+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and effectiveness of benralizumab in children with rare eosinophilic diseases. This open-label, multicenter Phase 3 study includes pediatric participants with eosinophilic granulomatosis with polyangiitis EGPA and hypereosinophilic syndrome HES, with potential for additional eosinophilic disease groups in future amendments. Participants will receive benralizumab as a subcutaneous injection every four weeks for 52 weeks. Dosing depends on weight children weighing 35 kg or more receive one dose, while those under 35 kg receive a different dose. After completing the first year, participants may continue treatment in an extension period for at least another year, with ongoing safety monitoring following the last dose. Throughout the study, participants will undergo screening for eligibility, followed by regular assessments including blood tests to measure benralizumab levels and eosinophil counts, monitoring for adverse events, and evaluations of disease remission and flare-ups. Additional safety tests and questionnaires will be conducted at scheduled visits. The total participation time includes screening, 52 weeks of treatment, and at least 52 weeks of extension with safety follow-up.

Age: 6Years - 17YearsAll GendersPhase 3
15 locations